Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
Novo Nordisk has entered a strategic partnership with OpenAI to integrate AI systems across its research, manufacturing, and commercial workflows. Initial pilot programs are expected across R&D, manufacturing, and commercial units, with broader rollout planned through 2026.
Novo plans to deploy AI tools across the full value chain, from early target identification and hypothesis generation to supply chain management and distribution, potentially shortening drug development timelines. In research, collaboration focuses on processing large biological and clinical datasets to identify patterns and potential drug candidates that may not be accessible through conventional analysis.
On the operational side, the partnership includes applications in manufacturing and logistics, where AI systems are expected to support process optimization, demand forecasting, and coordination across global supply networks. This reflects a broader shift among large pharmaceutical companies toward embedding AI not only in discovery pipelines but also in industrial and commercial infrastructure.
A central component of the collaboration is workforce development. OpenAI will support internal training programs aimed at increasing AI literacy across Novo Nordisk’s global organization, enabling scientific, technical, and operational teams to integrate AI tools into routine workflows.
The companies emphasise that the deployment will follow structured governance frameworks, including data protection controls and human oversight mechanisms.
The move builds on Novo Nordisk’s existing investments in AI partnerships.
- In January 2025, the company expanded its AI drug discovery partnership with Valo Health to cover up to 20 programs in obesity, type 2 diabetes, and cardiovascular disease.
- In June 2025, Novo Nordisk also teamed up with NVIDIA and Denmark’s DCAI to use the Gefion sovereign AI supercomputer for custom models, agentic workflows, and simulation-heavy research.
- It has also been building the enabling stack around that work through a Microsoft Research collaboration on an internal AI platform for research, regulatory, and trial-design use cases.
Other recent news also suggests OpenAI’s interest in biotech is moving beyond generic enterprise tooling and into pharma-specific workflows. Aside from testing a dedicated ChatGPT Healthcare suite, it has been expanding collaborations with large pharmaceutical companies including Sanofi, Moderna, and Eli Lilly.
- Sanofi and Formation Bio collaboration with OpenAI produced Muse, a tool focused on speeding clinical trial patient recruitment.
- In October 2025, Thermo Fisher extended that pattern into contract research and development infrastructure through a collaboration that initially targeted its PPD clinical research business and broader drug development workflows.
- OpenAI has also been deepening direct ties with drugmakers themselves: Moderna says it has worked with OpenAI since early 2023 and has rolled ChatGPT Enterprise out across thousands of employees.
- OpenAI’s other recent work with Retro Biosciences also applied a protein-focused GPT-4b variant to engineer Yamanaka factors.
Novo Nordisk and OpenAI partnership points to a gradual convergence where AI systems are becoming embedded across the full operating stack of large pharmaceutical companies.
For a more detailed view of how foundation models are being applied in biomedical contexts, and how approaches such as neurosymbolic systems and agents are being developed to address their limitations, see our deep dives: New LLMs, Agents, and Graphs in Life Sciences and Can AI Diagnose Better Than Humans?.
Topic: Industry Movers
